A Diabetes Study to Treat A Population previously Not at Target - ADAPT

Study identifier:D3560L00072

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

12-week, open-label, multi-center, prospective study evaluating the effect of individualizing starting doses of rosuvastatin according to baseline LDL (low density lipoprotein)-cholesterol levels on achieving cholesterol targets in type 2 diabetic patients

Medical condition

Type 2 Diabetes

Phase

Phase 4

Healthy volunteers

No

Study drug

Rosuvastatin

Sex

All

Actual Enrollment

598

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 May 2008
Primary Completion Date: 01 Aug 2009
Study Completion Date: 01 Aug 2009

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2011 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria